Head-to-head evidence
certolizumab pegol vs SFA-002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT02326272 · Phase 3 · completed
This was a randomized, double-blind (quadruple-masked), placebo-controlled trial in 227 adults with moderate-to-severe plaque psoriasis. Both the 200 mg and 400 mg certolizumab pegol doses produced significantly higher rates of skin clearance (PASI75: 81.4% and 82.6% vs 11.6% placebo) and physician-assessed clearance (66.8% and 71.6% vs 2.0% placebo) at week 16, both p<0.0001.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
SFA-002
Developed by SFA Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · SFA-002's landscape